Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcin Kowanetz

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Cell|April 8, 2010
PlGF blockade does not inhibit angiogenesis during primary tumor growthCarlos Bais, Xiumin Wu, Jenny Yao, et al.
Lancet (London, England)|December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockadeRomain Banchereau, Avantika S Chitre, Alexis Scherl, et al.
Nature Cancer|February 5, 2022
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityShelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Cell|April 8, 2010
PlGF blockade does not inhibit angiogenesis during primary tumor growthCarlos Bais, Xiumin Wu, Jenny Yao, et al.
Lancet (London, England)|December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockadeRomain Banchereau, Avantika S Chitre, Alexis Scherl, et al.
Nature Cancer|February 5, 2022
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityShelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, et al.
Pageof 5